As per the previously agreed terms, Mallinckrodt has paid InfaCare $80 million as upfront payment. InfaCare is eligible for additional milestone payments of up to $345 million on reaching certain ...

Infacare Pharmaceutical Corp has announced a $28 million private placement of its Series B Preferred Stock, led by HealthCare Ventures with participation from Longitude Capital, FirstMark Capital and ...

Discover more of our free reports coverage from other companies within the Drugs - Generic industry. Pro-TD has currently selected Allergan PLC (NYSE: AGN) for due-diligence and potential coverage as ...

TREVOSE, Pa., Oct. 27 -- InfaCare Pharmaceutical Corporation, a late stage specialty pharmaceutical company focused on the development of products to treat neonatal diseases, today announced a $28 ...

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, and InfaCare Pharmaceutical Corporation today announced that they have entered into an agreement under which ...

A Bucks County specialty drug company has raised $5.5 million, according to documents filed with the Securities and Exchange Commission. The company, InfaCare Pharmaceutical Corp. of Trevose, is ...

Trevose, PA-based InfaCare Pharmaceutical has rounded up $28 million for its Series B, with much of the money earmarked for a late-stage trial. HealthCare Ventures led the round and Harold Werner, a ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Mallinckrodt PLC is acquiring specialty pharmaceutical firm ...

Mallinckrodt plc said it plans to acquire Infacare Pharmaceutical Corp., the developer of a late-stage severe jaundice treatment, for $80 million up front plus up to $345 million in potential ...

Mallinckrodt PLC has closed its potential $425 million acquisition of InfaCare Pharmaceutical Corp. Mallinckrodt made an up-front payment of $80 million and could make additional payments of up to ...